1
|
Formenti P, Umbrello M, Pignataro M, Sabbatini G, Dottorini L, Gotti M, Brenna G, Menozzi A, Terranova G, Galimberti A, Pezzi A. Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update. J Pers Med 2024; 14:483. [PMID: 38793067 PMCID: PMC11122522 DOI: 10.3390/jpm14050483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 04/16/2024] [Accepted: 04/30/2024] [Indexed: 05/26/2024] Open
Abstract
Severe cancer pain substantially affects patients' quality of life, increasing the burden of the disease and reducing the disability-adjusted life years. Although opioid analgesics are effective, they may induce opioid-induced bowel dysfunction (OIBD). Oxycodone/naloxone combination therapy has emerged as a promising approach to mitigate opioid-induced constipation (OIC) while providing effective pain relief. This review provides an updated analysis of the literature of the last decade regarding the use of oxycodone/naloxone in the management of severe cancer pain. Through a comprehensive search of databases, studies focusing on the efficacy, safety, and patient experience of oxycodone/naloxone's prolonged release in severe cancer pain management were identified. Furthermore, the literature discusses the mechanism of action of naloxone in mitigating OIC without compromising opioid analgesia. Overall, the evidence suggests that oxycodone/naloxone combination therapy offers a valuable option for effectively managing severe cancer pain while minimizing opioid-induced constipation, thereby improving patients' quality of life. However, further research is needed to optimize dosing regimens, evaluate long-term safety, and assess patient outcomes in diverse cancer populations.
Collapse
Affiliation(s)
- Paolo Formenti
- SC Anestesia, Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, 20097 Milan, Italy
| | - Michele Umbrello
- Department of Intensive Care, New Hospital of Legnano (Ospedale Nuovo di Legnano), 20025 Legnano, Italy
| | | | - Giovanni Sabbatini
- SC Anestesia, Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, 20097 Milan, Italy
| | | | - Miriam Gotti
- SC Anestesia, Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, 20097 Milan, Italy
| | - Giovanni Brenna
- SC Anestesia, Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, 20097 Milan, Italy
| | - Alessandro Menozzi
- School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milano, Italy
| | - Gaetano Terranova
- Anaesthesia and Intensive Care Department, Asst Gaetano Pini, 20100 Milano, Italy
| | - Andrea Galimberti
- SC Anestesia, Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, 20097 Milan, Italy
| | - Angelo Pezzi
- SC Anestesia, Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo, 20097 Milan, Italy
| |
Collapse
|
2
|
Doherty M, Featherstone HJ, McAleer C, Webb C, O'Reilly M, Twomey M, McQuillan R. Opioid toxicity after oxycodone/naloxone to oxycodone conversion: case series. BMJ Support Palliat Care 2024:spcare-2024-004796. [PMID: 38408794 DOI: 10.1136/spcare-2024-004796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 02/06/2024] [Indexed: 02/28/2024]
Abstract
Combination preparations of oxycodone/naloxone are marketed to aid in the management of opioid induced bowel dysfunction, with caution advised in prescribing in cases of liver dysfunction.This case series demonstrates four cases of patients with normal liver function tests who developed significant opioid toxicity on conversion from combination oxycodone/naloxone to oxycodone at equivalent doses, necessitating significant dose reduction.In each case, a cause for intra-hepatic shunting such as cirrhosis, porto-systemic collaterals or thrombosis were identified, highlighting these as cautionary features when prescribing combination preparations of oxycodone/naloxone and the possible need for dose reduction if converting to oxycodone.
Collapse
Affiliation(s)
- Mairead Doherty
- St. Francis Hospice, Raheny, Dublin, Ireland
- Palliative Medicine, Mater Misericordiae University Hospital, Dublin, Ireland
| | | | - Clare McAleer
- St. Francis Hospice, Raheny, Dublin, Ireland
- Palliative Medicine, Beaumont Hospital, Dublin, Ireland
| | - Chloe Webb
- St. Francis Hospice, Raheny, Dublin, Ireland
| | - Maeve O'Reilly
- Specialist Palliative Medicine Service, St Luke's Radiation Oncology Network, Dublin 6, Ireland
| | - Marie Twomey
- Specialist Palliative Medicine Service, St Luke's Radiation Oncology Network, Dublin 6, Ireland
| | - Regina McQuillan
- Palliative Medicine, Beaumont Hospital, Dublin, Ireland
- Palliative Medicine, St Francis Hospice, Dublin 5, Ireland
| |
Collapse
|
3
|
Sachdeva R, Hosseinzadeh A, Rizzardo A, Maharaj A, Berger M, Krassioukov A. No pain, no strain: Targin® mitigates pain and constipation following spinal cord injury. Ann Clin Transl Neurol 2023; 10:453-458. [PMID: 36692221 PMCID: PMC10014000 DOI: 10.1002/acn3.51734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 12/30/2022] [Accepted: 01/10/2023] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Opioids effectively reduce chronic pain, but present significant side effects including opioid-induced constipation. Oxycodone/naloxone decreases pain and constipation in cancer patients, however its effect on spinal cord injury population remains understudied. METHODS We assessed whether oxycodone/naloxone reduces pain, constipation, and severity of autonomic dysreflexia in an individual with spinal cord injury. A 55-year-old male with C5 lesion presented with chief complaint of chronic pain received 5/2.5 mg and 20/10 mg oxycodone/naloxone for 6 and 2 weeks, respectively. RESULTS Oxycodone/naloxone improved pain, bowel function, and autonomic dysreflexia severity. INTERPRETATION Oxycodone/naloxone was effective in managing chronic pain and constipation in the studied case.
Collapse
Affiliation(s)
- Rahul Sachdeva
- International Collaboration on Repair Discoveries, University of British Columbia, British Columbia, Vancouver, Canada
| | - Ali Hosseinzadeh
- International Collaboration on Repair Discoveries, University of British Columbia, British Columbia, Vancouver, Canada
| | - Aaron Rizzardo
- Department of Medicine, Division of Community Internal Medicine, University of British Columbia, British Columbia, Vancouver, Canada
| | - Andrea Maharaj
- International Collaboration on Repair Discoveries, University of British Columbia, British Columbia, Vancouver, Canada
| | - Michael Berger
- International Collaboration on Repair Discoveries, University of British Columbia, British Columbia, Vancouver, Canada.,Department of Medicine, Division of Physical Medicine and Rehabilitation, University of British Columbia, British Columbia, Vancouver, Canada
| | - Andrei Krassioukov
- International Collaboration on Repair Discoveries, University of British Columbia, British Columbia, Vancouver, Canada.,Department of Medicine, Division of Physical Medicine and Rehabilitation, University of British Columbia, British Columbia, Vancouver, Canada.,Spinal Cord Program, GF Strong Rehabilitation Centre, University of British Columbia, British Columbia, Vancouver, Canada
| |
Collapse
|
4
|
Zhu X, Xu Y, Shen Z, Zhang H, Xiao S, Zhu Y, Wu M, Chen Y, Wu Z, Xu Y, He X, Liu B, Liu J, Du J, Sun J, Fang J, Shao X. Rostral Anterior Cingulate Cortex–Ventrolateral Periaqueductal Gray Circuit Underlies Electroacupuncture to Alleviate Hyperalgesia but Not Anxiety-Like Behaviors in Mice With Spared Nerve Injury. Front Neurosci 2022; 15:757628. [PMID: 35095390 PMCID: PMC8789679 DOI: 10.3389/fnins.2021.757628] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Accepted: 12/20/2021] [Indexed: 11/16/2022] Open
Abstract
Neuropathic pain is a common cause of chronic pain and is often accompanied by negative emotions, making it complex and difficult to treat. However, the neural circuit mechanisms underlying these symptoms remain unclear. Herein, we present a novel pathway associated with comorbid chronic pain and anxiety. Using chemogenetic methods, we found that activation of glutamatergic projections from the rostral anterior cingulate cortex (rACCGlu) to the ventrolateral periaqueductal gray (vlPAG) induced both hyperalgesia and anxiety-like behaviors in sham mice. Inhibition of the rACCGlu-vlPAG pathway reduced anxiety-like behaviors and hyperalgesia in the spared nerve injury (SNI) mice model; moreover, electroacupuncture (EA) effectively alleviated these symptoms. Investigation of the related mechanisms revealed that the chemogenetic activation of the rACCGlu-vlPAG circuit effectively blocked the analgesic effect of EA in the SNI mice model but did not affect the chronic pain-induced negative emotions. This study revealed a novel pathway, the rACCGlu-vlPAG pathway, that mediates neuropathic pain and pain-induced anxiety.
Collapse
|